Dr. Saylor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit Street
Yawkey 7E
Boston, MA 02114Phone+1 617-724-4000Fax+1 617-726-8685- Is this information wrong?
Summary
- Dr. Philip Saylor is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from University of Pittsburgh School of Medicine and has been in practice 14 years. He specializes in genitourinary oncology and hematologic oncology and is experienced in amyloidosis, hematologic oncology, prostate cancer, myelodysplasia, and myelofibrosis.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2003 - 2006
- University of Pittsburgh School of MedicineClass of 2003
Certifications & Licensure
- ME State Medical License 2020 - 2025
- MA State Medical License 2008 - 2025
- CA State Medical License 2005 - 2025
- NH State Medical License 2021 - 2025
- RI State Medical License 2021 - 2024
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer Start of enrollment: 2010 Sep 01
Publications & Presentations
PubMed
- Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature.Mei, S., Alchahin, A., Embaie, B., Gavriliuc, I., Verhoeven, B., Zhao, T., Li, X., Jeffries, N., Pepich, A., Sarkar, H., Olsen, T., Wickström, M., Stenman, J., Reina-B...> ;JCI Insight. 2024 Feb 15
- Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer.Saylor, P., Otani, K., Balza, R., Ukleja, J., Pleskow, H., Fisher, R., Kusaka, E., Otani, Y., Badusi, P., Smith, M., Meneely, E., Olivier, K., Lowe, A., Toner, M., Mah...> ;JCO Precision Oncology. 2024 Feb 1
- Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions.Mei, S., Alchahin, A., Tsea, I., Kfoury, Y., Hirz, T., Jeffries, N., Zhao, T., Xu, Y., Zhang, H., Sarkar, H., Wu, S., Subtelny, A., Johnsen, J., Zhang, Y., Salari, K.,...> ;Genome Medicine. 2024 Jan 29
- Join now to see all
Press Mentions
- Outside the Guidelines: Denosumab Overuse in Prostate CancerMarch 7th, 2024
- SUO 2023: Bone Support Throughout the Prostate Cancer JourneyNovember 30th, 2023
Professional Memberships
- Member
Hospital Affiliations
- Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: